
ITGR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ITGR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ITGR and 80,000+ other tickers.
See exactly how ITGR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ITGR and 80,000+ other tickers.
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions…

PLANO, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), announced today that it will webcast its conference call to discuss financial results and business highlights for the second quarter ended July 3, 2026, on Thursday, Aug. 6, 2026, at 8 a.m. CT (9 a.m. ET). Other forward-looking and material information may also be discussed during the call.

ITGR resets its 2026 outlook after customer forecast changes and slower product ramps, with growth and margin recovery tied to adoption timing.

PLANO, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced participation in the Truist Securities 2026 MedTech Conference, to be held June 16, 2026. Members of the Integer executive leadership team will participate in a fireside chat on Tuesday, June 16 at 10:40 a.m. ET.

There is a principle I have followed for 30 years in this business. When the smartest credit team on the planet starts aggressively buying a beaten-down asset class they understand better than anyone alive, you do not sit on your hands and debate whether the timing is perfect.

Integer Holdings Corp. is a unique, high-quality medical device CDMO trading at a depressed ~10x EBITDA multiple after a temporary growth slowdown. A strategic review, prompted by activist involvement and heightened buyer interest, positions ITGR for a likely sale within three to four months. Precedent CDMO transactions support a fair value of $110–125/share (13–14x forward EBITDA), offering 20–40% upside with limited downside risk.